Co Development Partners Carrick has a portfolio of first in class cancer therapies and existing collaborations with leading pharma companies, signaling a strong appetite for strategic co development and licensing. Business development opportunities include expanding samuraciclib combinations into additional indications and sharing development costs and commercialization rights with partners. The company’s global clinician and scientist network can accelerate trial design, patient access, and regulatory readiness across regions.

Precision Diagnostics Carrick's tumor tailored strategy creates demand for companion diagnostics and biomarker platforms. Partners in diagnostics and CROs can co-develop tests, enabling precise patient selection, streamlined trial endpoints, and stronger evidence for regulatory submissions.

Trial Network Expansion Their network of clinicians and scientists in leading research institutes and hospitals can be leveraged for faster patient recruitment and diverse site access. Potential services include CRO partnerships, site management, trial logistics, and cross border enrollment to accelerate timelines.

Digital Trial Platform The tech stack shows investments in web and digital engagement; there is scope to co create or license a digital trial platform for patient portals, e consent, ePRO, secure data capture, and analytics. This can improve patient experience, trial efficiency, and data quality, with potential monetization via platform licensing or services.

Funding Synergy With active investment from major pharma and ongoing rounds, Carrick may be open to strategic sponsorships, co funding of trials, or joint ventures. Business development outreach to venture arms and corporate strategic investors could align funding with program milestones, expanding speed to market and commercialization options.